CoChat

The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer

Open access
Hanrahan, Karen, O'Neill, Amanda, Prencipe, Maria, Bugler, Jane, Murphy, Lisa, Fabre, Aurelie, Puhr, Martin, Culig, Zoran, Murphy, Keefe, Watson, R. William · 2017 · Molecular Oncology
Cited by 124

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Docetaxel is the main treatment for advanced castration‐resistant prostate cancer; however, resistance eventually occurs. The development of intratumoral drug‐resistant subpopulations possessing a cancer stem cell (CSC) morphology is an emerging mechanism of docetaxel resistance, a process driven by epithelial–mesenchymal transition (EMT). This study characterised EMT in docetaxel‐resistant sublines through increased invasion, MMP‐1 production and ZEB 1 and ZEB 2 expression. We also present evidence for differential EMT across PC‐3 and DU 145 in vitro resistance models as characterised by differential migration, cell colony scattering and susceptibility to the CSC inhibitor salinomycin. si RNA manipulation of ZEB 1 and ZEB 2 in PC‐3 and DU 145 docetaxel‐resistant sublines identified ZEB 1, through its transcriptional repression of E‐cadherin, to be a driver of both EMT and docetaxel resistance. The clinical relevance of ZEB 1 was also determined through immunohistochemical tissue microarray assessment, revealing significantly increased ZEB 1 expression in prostate tumours following docetaxel treatment. This study presents evidence for a role of ZEB 1, through its transcriptional repression of E‐cadherin to be a driver of both EMT and docetaxel resistance in docetaxel‐resistant prostate cancer. In addition, this study highlights the heterogeneity of prostate cancer and in turn emphasises the complexity of the clinical management of docetaxel‐resistant prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12030

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 124

Metadata

Authors
Hanrahan, K., O'Neill, A., Prencipe, M., Bugler, J., Murphy, L., Fabre, A., Puhr, M., Culig, Z., Murphy, K., & Watson, R. W.
Venue
Molecular Oncology
Publisher
Wiley
Published
2017-01-30
Volume
11
Issue
3
Pages
251-265
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2582775233
Cited by
124
References
8
FWCI
10.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer. https://app.cochat.ai/papers/10.1002/1878-0261.12030
The paper
Hanrahan, K., O'Neill, A., Prencipe, M., Bugler, J., Murphy, L., Fabre, A., Puhr, M., Culig, Z., Murphy, K., & Watson, R. W. (2017). The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.12030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.